GlassScriptPhysician profile
Scott S Brehaut
NPI 1245253541
$513,914.19
in general payments reported to CMS, 2019-2025
57 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123K · 2020: $54K · 2021: $132K · 2022: $105K · 2023: $45K · 2024: $30K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Food and Beverage: $6,699 · Travel and Lodging: $5,265 · Honoraria: $500 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,641.00 |
| Food and Beverage | $6,698.62 |
| Travel and Lodging | $5,264.87 |
| Honoraria | $500.00 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $212,837.71 | 2019-2024 | Xarelto |
| Chiesi USA, INC. | $112,871.64 | 2019-2025 | Cleviprex |
| Avanir Pharmaceuticals, INC. | $81,555.67 | 2019-2022 | |
| Abbvie INC. | $61,610.41 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Biogen, INC. | $33,108.90 | 2020-2021 | |
| Allergan, INC. | $1,107.25 | 2019-2022 | |
| Ucb, INC. | $987.30 | 2019-2024 | Briviact, Nayzilam |
| Sk Life Science, INC. | $976.63 | 2020-2025 | Xcopri |
| Amgen INC. | $795.55 | 2019-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $609.20 | 2019-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $605.11 | 2019-2024 | Emgality, Amyvid, Kisunla |
| Teva Pharmaceuticals USA, INC. | $552.45 | 2020-2023 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $508.29 | 2019-2024 | |
| Pfizer INC. | $481.49 | 2019-2024 | |
| Eisai INC. | $479.33 | 2020-2024 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $419.55 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Neurocrine Biosciences, INC. | $382.21 | 2022-2024 | Ingrezza, Ongentys |
| Astellas Pharma US INC | $329.95 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $327.44 | 2021-2024 | Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $315.28 | 2019-2021 | |
| Axsome Therapeutics, INC. | $300.09 | 2022-2024 | Auvelity, Sunosi |
| Biohaven Pharmaceuticals, INC. | $257.11 | 2021 | |
| Amarin Pharma, INC. | $210.07 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $195.40 | 2022 | |
| Fidia Pharma USA INC. | $176.09 | 2019-2024 | Triluron, Hyalgan, Hymovis |
| Boston Scientific Corporation | $167.36 | 2022-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $166.68 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $134.40 | 2023-2024 | Rexulti, Nuedexta |
| Mylan Specialty L.P. | $124.49 | 2023 | Yupelri |
| Medtronic, INC. | $115.87 | 2022 | |
| Idorsia Pharmaceuticals US INC | $93.89 | 2022-2023 | Quviviq |
| Medtronic USA, INC. | $92.05 | 2019 | |
| Merz North America, INC. | $78.36 | 2019 | |
| Baxter Healthcare | $65.98 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Arbor Pharmaceuticals, INC. | $62.49 | 2020-2022 | |
| Abbott Laboratories | $58.89 | 2022-2024 | Freestyle Libre 2 |
| Upsher-Smith Laboratories LLC | $58.78 | 2020-2021 | |
| Integra Lifesciences Corporation | $55.42 | 2022 | |
| Scilex Pharmaceuticals INC. | $53.22 | 2019 | |
| Amneal Pharmaceuticals LLC | $48.06 | 2024 | Ongentys, Rytary |
| Sumitomo Pharma America, INC. | $45.45 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.48 | 2019-2024 | Ofev |
| Lundbeck LLC | $43.77 | 2021-2024 | Rexulti |
| Glaxosmithkline, LLC. | $41.30 | 2024 | Trelegy Ellipta |
| Ibsa Pharma INC. | $40.93 | 2019-2023 | Tirosint, Licart |
| Almatica Pharma LLC | $40.92 | 2021 | |
| Horizon Therapeutics Plc | $39.93 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $36.27 | 2022 | |
| Genentech USA, INC. | $33.58 | 2020-2021 | |
| Exact Sciences Corporation | $32.62 | 2023 | Cologuard Collection Kit |
| Portola Pharmaceuticals, LLC | $32.60 | 2019 | |
| Shield Therapeutics INC | $19.00 | 2023 | Accrufer |
| Bardy Diagnostics, INC. | $18.70 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.44 | 2024 | Keveyis |
| Ipsen Biopharmaceuticals, INC | $18.00 | 2023 | Dysport |
| Azurity Pharmaceuticals, INC. | $17.66 | 2023 | Horizant |
| Takeda Pharmaceuticals U.S.A., INC. | $14.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Brehaut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.